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Abstract
Introduction: The ability to screen blood of early stage operable breast cancer patients for
circulating tumour cells is of potential importance for identifying patients at risk of developing
distant relapse. We present the results of a study of the efficacy of the immunobead RT-PCR
method in identifying patients with circulating tumour cells.
Results:  Immunomagnetic enrichment of circulating tumour cells followed by RT-PCR
(immunobead RT-PCR) with a panel of five epithelial specific markers (ELF3, EPHB4, EGFR, MGB1
and TACSTD1) was used to screen for circulating tumour cells in the peripheral blood of 56 breast
cancer patients.
Twenty patients were positive for two or more RT-PCR markers, including seven patients who
were node negative by conventional techniques. Significant increases in the frequency of marker
positivity was seen in lymph node positive patients, in patients with high grade tumours and in
patients with lymphovascular invasion. A strong trend towards improved disease free survival was
seen for marker negative patients although it did not reach significance (p = 0.08).
Conclusion: Multi-marker immunobead RT-PCR analysis of peripheral blood is a robust assay that
is capable of detecting circulating tumour cells in early stage breast cancer patients.
Introduction
RT-PCR of peripheral blood mononuclear cells (PBM-
NCs) using lineage-specific markers is the most common
published methodology for the detection of circulating
tumour cells (CTCs) in the peripheral blood. RT-PCR was
first used to detect circulating melanoma [1] and neurob-
lastoma cells [2]. Due to the high levels of sensitivity nec-
essary to detect rare cancer cells, nested RT-PCR is often
used and therefore even low levels of illegitimate tran-
scription in PBMNCs can cause false positive results [3-5].
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Nested RT-PCR is also time consuming and stringent pro-
cedures need to be observed in order to minimize the risk
of false positives due to PCR product cross contamination.
We developed the immunobead PCR methodology using
immunomagnetic beads coated with an epithelial cell spe-
cific antibody to enrich carcinoma cells from whole blood
[6]. When blood from a patient is incubated with anti-
body-coated beads, the beads attach to any epithelial cells
that might be in the blood. The justifiable assumption is
that the only epithelial cells in blood or bone marrow are
carcinoma cells. A magnet can then be used to harvest
these cells. A modification combining immunobead
enrichment with RT-PCR detection of lineage-specific
markers (immunobead RT-PCR, IB RT-PCR) was subse-
quently developed [7]. This minimised the problem of
illegitimate transcription, allowed the use of whole blood
rather than the mononuclear cell fraction, and eliminated
the requirement for nested RT-PCR.
We subsequently reported a strategy to identify sensitive
and specific RT-PCR assays to be used in immunobead RT-
PCR analysis [8]. This method allowed the selection of a
panel of RT-PCR markers suitable for immunobead RT-
PCR. These included 2 novel markers ELF3 (also known as
ESX) and EPHB4, as well as the previously used markers
epidermal growth factor receptor (EGFR), TACSTD1 (also
known as epithelial cell adhesion molecule – EpCAM)
and mammaglobin 1 (MGB1). These markers were both
sensitive enough to enable detection of a single tumour
cell and specific enough not to be amplified from PBM-
NCs that may contaminate the immunobead-tumour cell
pellet. In this new report, we assessed this panel of mark-
ers in a prospective study using peripheral blood samples
from 56 predominantly early stage breast cancer patients.
Methods
Patient samples
Peripheral blood (10 ml) was collected in potassium
EDTA tubes from 56 breast cancer patients ranging in age
from 37–89 years who presented for pre-admission coun-
selling prior to surgery at The Queen Elizabeth Hospital,
Adelaide, Australia. The first 2 ml of blood was discarded
to avoid contamination from the skin puncture. Periph-
eral blood was also collected from 10 normal individuals
for use as negative control samples and in reconstruction
experiments. Informed consent was obtained in all cases
and ethics approval for this study was obtained from The
Queen Elizabeth Hospital Ethics of Human Research
Committee. The distribution of tumours according to the
TNM classification system was 8 in situ, 17 Stage I, 21
Stage IIA, 9 Stage IIB, 1 Stage IIIA.
Cell lines
The breast cancer cell lines MDA-MB-231, MDA-MB-468,
MDA-MB-453 and MCF7 were maintained in Dulbecco's
Modified Eagle Medium (Invitrogen, Carlsbad, CA) in 75
cm2 tissue culture flasks at 37°C in a 5% CO2 environ-
ment. The medium was supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin, 160 μg/ml L-
glutamine and 10% heat-inactivated foetal bovine serum
(CSL, Melbourne, Australia). Cells were collected at <
90% confluency by trypsin digestion and centrifugation
for 5 min at 1000 rpm, resuspended in phosphate buff-
ered saline (PBS) and counted using a haemocytometer.
Reconstruction experiments
MDA-MB-453 cells were diluted in PBS and counted to
give aliquots containing 10, 100, and 1000 cells. Tripli-
cate aliquots were seeded into 10 ml of normal blood and
analysed by immunobead enrichment and RT-PCR. Nor-
mal donor blood with no cells added was used as a nega-
tive control.
Immunobead-enrichment and RT-PCR detection of 
circulating epithelial cells
The immmunobead RT-PCR technique has been
described previously [7]. Briefly, each 10 ml patient blood
sample was incubated with 4 million immunomagnetic
Dynabeads M-450 (Dynal, Oslo, Norway), labelled with
the monoclonal antibody BerEP4 (Dako, Gestrop, Den-
mark). Each tube was placed on a low speed-rotating
mixer for 2 h at 4°C. Bead rosetted cells were isolated in
each tube using a magnetic array (Dynal), enabling the
beads to be washed 3 times in PBS to remove unbound
PBMNCs. The bead/cell isolates were then transferred to a
microcentrifuge tube.
The captured cells were then lysed in a 9.5 μl volume of
solution containing 0.3% v/v Nonidet P-40 detergent
(Sigma), 500 ng random hexamers (Pharmacia, Uppsala,
Sweden), 20 U of RNasin (Promega, Madison, WI) and 10
mM DTT, then stored at -80°C until needed for reverse
transcription. Reverse transcription was initiated by the
addition of 5× First Strand Buffer, 200 U of Superscript II
(Invitrogen), 0.5 mM of each deoxynucleotide triphos-
phate (Roche Applied Science, Mannheim, Germany),
with ultra-pure water (Fisher Biotech, Perth, Australia) to
a final volume of 20 μl. The reaction was incubated at
42°C for 50 min, and then the reverse transcriptase reac-
tion was inactivated by incubation at 70°C for 10 min.
After reverse transcription, 3.9 μl of cDNA was used as the
template in a single round of PCR amplification with 200
nM of each gene specific primer pair (Table 1), 1 U of Hot-
StarTaq (Qiagen, Hilden, Germany), 2.5 mM MgCl2, and
200 μM of each deoxynucleotide triphosphate, in the sup-
plied PCR buffer. Cycling conditions included an initialJournal of Hematology & Oncology 2009, 2:24 http://www.jhoonline.org/content/2/1/24
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denaturation step at 95°C for 15 min, then 1 min at each
of 94°C, 66–68°C and 72°C for 45 – 55 cycles and a final
extension of 7 min at 72°C. Amplification products were
visualised by ethidium bromide staining following sepa-
ration by electrophoresis through agarose gels. In each
case, a negative control for the RT reaction, made up of the
components of the RT reaction mixture with or without
lysis mix, and without the addition of RNA, was used as
the template in the PCR reaction (no cDNA made and
therefore no amplification expected). The PCR negative
control contained the reagents of the PCR reaction but
lacked template. Cell line cDNA was included as a positive
control for the PCR reaction. Genomic DNA (100 ng) was
used to confirm that a product of equal size to the cDNA
product would not be amplified from the DNA in the cell
lysate.
Statistical Analysis
Clinical follow-up was obtained through the Cancer Reg-
istry database at The Queen Elizabeth Hospital for the
patients enrolled in the study. The database included dis-
ease stage (TNM staging system), tumour size and grade,
ER/PR status, presence or absence of lymphovascular
invasion, and date and cause of death. Frequency data was
analysed with the Fisher Exact Test. Metastasis free sur-
vival was estimated with Kaplan Meier curves [9] which
were compared with the log rank Test [10]. All statistical
tests were two sided and p < 0.05 was considered to be sta-
tistically significant. All statistical tests were performed
using SPSS (version 16 Chicago, Illinois, USA).
Results
Sensitivity experiment
Ten, hundred and thousand cell aliquots of the MDA-MB-
453 cell line were seeded into triplicate ten ml tubes con-
taining blood from a single normal donor and evaluated
for the sensitivity of detection of the five immunobead
RT-PCR markers (Figure 1). Blood samples containing no
added cells were negative for all markers. Blood samples
containing an estimated 100 or 1000 seeded cells were
positive for all 5 markers in 3/3 replicates. In samples con-
taining an estimated 10 seeded cells, TACSTD1  was
detected in 2/3 replicates, ELF3 was detected in 2/3 repli-
cates,  EGFR  was detected in 1/3 replicates, EphB4  was
detected in 1/3 replicates while MGB1 was not detected.
No other markers were positive in the samples that were
negative for TACSTD1 suggesting that no MDA-MB-453
cells were captured with the BerEp4-conjugated beads
from these samples as TACSTD1 codes for EpCAM which
BerEp4 recognises.
Immunobead RT-PCR analysis of blood samples
The expression of each of the five RT-PCR markers was
assessed in the immunomagnetically enriched fraction of
blood samples obtained prior to surgery from 56 early
stage breast cancer patients (Table 2). One hundred nan-
Table 1: RT-PCR primers and PCR conditions.
Primer name GenBank Accession Number Sequence 5' – 3' PCR annealing temperature Size
ELF3 sA F 0 1 6 2 9 5 CTCGGAGCTCCCACTCCTCAGA
ELF3 as GCTCTTCTTGCCCTCGAGACAGT 68°C 188 bp
EPHB4 s AB209644 CCCCAGGGAAGAAGGAGAGCTG
EPHB4 as GCCCACGAGCTGGATGACTGTG 68°C 250 bp
EGFR s AB209442 TGTGAGGTGGTCCTTGGGAATTTGG
EGFR as TGCTGACTATGTCCCGCCACTGGA 66°C 339 bp
TACSTD1 s BC014785 GGACCTGACAGTAAATGGGGAAC
TACSTD1 as CTCTTCTTTCTGGAAATAACCAGCAC 68°C 186 bp
MGB1 sA Y 2 1 7 1 0 0 CGGATGAAACTCTGAGCAATGTTGAG
MGB1 as CTGCAGTTCTGTGAGCCAAAGGTC 68°C 110 bp
Sequences are shown for sense (s) and antisense (as) primers. The annealing temperatures used for the PCR reactions and the PCR product sizes 
are also shown.Journal of Hematology & Oncology 2009, 2:24 http://www.jhoonline.org/content/2/1/24
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ograms of cDNA from MDA-MB-468, MCF7, MDA-MB-
453, or MDA-MB-231 breast cancer cell lines were used as
positive controls for each RT-PCR assay.
In 20 cases, at least two markers were positive (36%). Of
these 20 cases, 8/20 (40%) showed expression of all five
markers, 8 (40%) were positive for four markers, 3 (15%)
were positive for three markers, and 1 case (5%) was pos-
itive for two markers. Two patients, one positive for ELF3
only (patient 6), and one for TACSTD1 only (patient 15)
were excluded from analysis because it was considered
unlikely these results were due to disseminated disease
(see Discussion). Blood samples from 10 normal donors
were analysed in an identical manner to those blood sam-
ples obtained from breast cancer patients, and were found
negative for all RT-PCR markers (data not shown).
Expression of RT-PCR markers by stage
The expression of RT-PCR markers was evaluated by clin-
ical stage for the 56 patient samples (Table 2, column des-
ignated Stage). Positive RT-PCR marker expression was
detected in 1/8 (12.5%) patients considered to have in situ
disease, 3/17 (17.6%), patients with Stage I disease, 7/21
(33.3%) patients with Stage IIa disease, 8/9 (88.8%)
patients with Stage IIb disease and the one patient with
Stage IIIa disease.
In a comparison of in situ and stage I patients versus Stage
IIa and Stage IIb patients, there was a statistically signifi-
cant increase in the frequency of marker positivity in the
higher stage patients (p = 0.008). There was also a statisti-
cally significant increase in the frequency of marker posi-
tivity for Stage IIa versus Stage IIb patients (p = 0.007).
Expression of RT-PCR markers by tumour size
Nine of the 28 patients (32%) that had tumours ≤ 2 cm in
greatest dimension (T1) were RT-PCR positive (Table 2,
column T). Eight of the 19 patients (42%) that had
tumours > 2 cm but not more than 5 cm (T2) were RT-
PCR positive. Both patients with tumours > 5 cm (T3)
were RT-PCR positive. When in situ and T1 patients were
compared to T2 and T3 patients, the observed trend to
increasing numbers of patients that were positive for PCR
markers did not reach significance (p = 0.08).
Expression of RT-PCR markers by lymph node status
Lymph node involvement for all patients in the study had
been assessed using haemotoxylin and eosin staining
(Table 2). Certain patients had their sentinel lymph nodes
also assessed by immunohistochemistry. In total, 15/56
(27%) patients showed metastasis to one or more lymph
nodes. Eleven of the 15 (73%) patients with positive
lymph nodes were also positive for expression of RT-PCR
markers in blood. Two of three patient's where lymph
node involvement could not be assessed, were marker
positive. Importantly, 7/41 (17%) patients who were con-
sidered node negative by conventional techniques were
positive for at least two of the RT-PCR markers, with six of
these patients showing positive expression of three or
more markers. Nevertheless, lymph node positive patients
were more likely to be RT-PCR positive (p = 0.00015).
Expression of RT-PCR markers by grade
Of the 56 patients, 18 were classified as having Bloom and
Richardson Grade I (well differentiated) tumours, 20 were
classified as Grade II (moderately differentiated) tumours
and 12 were classified as Grade III (poorly differentiated)
tumours (Table 2). For six patients, Bloom and Richard-
son grading was not available. Five of 18 (28%) Grade I
patients, 6/20 (30%) Grade II patients, 8/12 (66%) Grade
III patients, and 1/6 patients where tumour grading was
not available, were RT-PCR positive. RT-PCR marker pos-
itivity was statistically higher (p = 0.01) in patients with
Grade 3 tumours compared to those with Grade 1 and 2
tumours.
IB RT-PCR sensitivity test on dilutions of MDA-MB-453 in  normal blood Figure 1
IB RT-PCR sensitivity test on dilutions of MDA-MB-
453 in normal blood. Cells were added to 10 mls of nor-
mal blood. Lane 1, M = pUC19/HpaII marker. Lanes 2–4, no 
added cells. Lanes 5–7, 10 added cells. Lanes 8–10, 100 added 
cells, Lanes 11–13, 1000 added cells. Lane 14, C = cDNA 
positive control. Lane 15, R = RT negative control. Lanes 16–
18, N = PCR negative controls. Product size is shown in base 
pairs (bp). A genomic DNA band is seen above the RT-PCR 
band for ELF3. The legend shows cells/10 ml of blood.
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Table 2: Clinical details and RT-PCR positivity data.
Stage T N ER PR Grade LVI TACSTD1 EPHB4 ELF3 EGFR MGB1
1 in situ Tis - xxN D - - - - - -
2 in situ Tis - ++N D - - - - - -
3 in situ Tis - --N D - - - - - -
4 in situ Tis - ++N D - - - - - -
5 in situ Tis - xxN D - - - - - -
6 in situ Tis - xxN D - - - + - -
7 in situ T i s - xxN D - + + + + -
8 In situ Tis x ++2 - - - - - -
9 I T 1 - ++1 - - - - - -
10 I T1 - + - 1 - - - - - -
1 1 I T 1 - ++1 - - - - - -
1 2 I T 1 - ++1 - - - - - -
1 3 I T 1 - ++1 - - - - - -
1 4 I T 1 - ++1 - - - - - -
1 5 I T 1 - ++1 - - - - -
1 6 I T 1 - ++1 - + - - - -
1 7 I T 1 - ++1 - + + - + -
1 8 I T 1 - ++2 - - - - - -
1 9 I T 1 - ++2 - - - - - -
20 I T1 - - + 2 - - - - - -
2 1 I T 1 - ++2 - - - - - -
2 2 I T 1 - --3 - + + - - -
2 3 I T 1 - ++3 - - - - - -
2 4 I T 1 - ++3 + + + + - -
25 I T1 - - + ND - - - - - -
26 IIa T1 + + - 1 - + + + + +
2 7 I I a T 1 + ++1 - - - - - -
2 8 I I a T 1 + ++2 - + + + + +Journal of Hematology & Oncology 2009, 2:24 http://www.jhoonline.org/content/2/1/24
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2 9 I I a T 1 + ++2 - + + + + +
3 0 I I a T 1 + ++2 + + + + + +
3 1 I I a T 1 + xx2 + - - - - -
3 2 I I a T 1 + ++2 - - - - - -
33 IIa T1 + - + 3 - + + + + -
3 4 I I a T 2 - xx1 - - - - - -
3 5 I I a T 2 - ++1 - - - - - -
3 6 I I a T 2 - ++1 - - - - - -
3 7 I I a T 2 - ++1 - - - - - -
3 8 I I a T 2 - ++1 + + + + - -
3 9 I I a T 2 - ++1 + + + + + -
4 0 I I a T 2 - ++2 - - - - - -
4 1 I I a T 2 - ++2 - - - - - -
4 2 I I a T 2 - ++2 + - - - - -
4 3 I I a T 2 - ++2 - - - - - -
4 4 I I a T 2 - ++2 + - - - - -
4 5 I I a T 2 - --3 - - - - - -
4 6 I I a T 1 - ++2 - - - - - -
4 7 I I b T 2 + ++1 - + + + + -
4 8 I I b T 2 + xx2 + + + + + +
4 9 I I b T 2 + ++3 + + + + + +
5 0 I I b T 2 + ++3 - + + + + +
51 IIb T2 + + - 3 + + + + + -
5 2 I I b T 2 + --3 + - - - - -
5 3 I I b T 3 - --3 + + + + + -
5 4 I I b T 1 x --2 + + + + + +
5 5 I I b T 2 x --3 + + + + + -
56 IIIa T3 + x x 2 - + + + + -
Stage, tumour size (T), nodal status (N), estrogen receptor status (ER) and progesterone receptor status (PR), lymphovascular invasion (LVI), 
tumour grade, and positive or negative expression of the 5 RT-PCR markers are shown for the 56 breast cancer patients. ND denotes no data. x 
denotes unknown.
Table 2: Clinical details and RT-PCR positivity data. (Continued)Journal of Hematology & Oncology 2009, 2:24 http://www.jhoonline.org/content/2/1/24
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Expression of RT-PCR markers by lymphovascular invasion 
(LVI)
Fourteen patients were determined to have LVI present
(Table 2, column LVI) and 10/14 (71%) were RT-PCR
positive. LVI was not observed in 42 patients and of these,
10/42 (24%) were RT-PCR positive. The association of LVI
and RT-PCR positivity was statistically significant (p =
0.002). LVI did not appear to be associated with grade,
nodal status, or ER/PR status. There was however, a ten-
dency for LVI to be associated with stage of disease and
tumour size with the majority of patients that were LVI
positive being Stage IIa or above with tumours classified
as T2.
Expression of RT-PCR markers by ER/PR status
ER/PR status was available for 48 of the 56 patients. Of the
38 ER positive patients, 12 (31%) were positive for RT-
PCR markers and 5/10 (50%) of the ER negative patients
were positive. Of the 38 PR positive patients, 11 (29%)
were marker positive, and of the 10 PR negative patients,
6 (60%) were marker positive. There was no significant
association with ER status and marker positivity (p = 0.2)
although there was a trend towards marker positivity in
ER negative patients. There was a marginally significant
association found between marker positivity and PR sta-
tus (p = 0.04).
Individual RT-PCR Marker expression
Transcripts corresponding to TACSTD1 and EPHB4 were
amplified in 20/20 (100%) of cases. Transcripts corre-
sponding to ELF3  were amplified from 18/20 (90%),
EGFR  from 17/20 (85%), and MGB1  transcripts were
amplified from 8/20 (40%) of samples. There appeared to
be no strong association with the individual expression of
TACSTD1, EPHB4, ELF3 and EGFR and any of the prog-
nostic factors examined above (data not shown). A repre-
sentative group of patients positive for IB RT-PCR marker
expression is presented in Figure 2.
Survival analysis
Kaplan-Meier survival analysis was performed using recur-
rence or death from disease as endpoints. The log-rank
test was used to compare survival curves of breast cancer
patients positive or negative for RT-PCR markers. There
was no significant difference between the 2 groups (p =
0.09) (Figure 3) but a strong trend was seen towards
poorer survival for patients positive for RT-PCR markers.
Discussion
Identification of epithelial cells in the peripheral blood of
patients with breast cancer may be used to identify
patients in whom haematogenous dissemination of
tumour cells has occurred. However, the prognostic rele-
vance of CTCs in the blood of patients with early stage dis-
ease, without overt metastasis, is still under investigation.
IB RT-PCR analysis for a representative group of 10 breast  cancer patients Figure 2
IB RT-PCR analysis for a representative group of 10 
breast cancer patients. Patient number corresponds to 
numbers provided in Table 2. Product sizes are shown in 
base pairs. M = pUC19/HpaII marker. A genomic DNA band 
is seen above RT-PCR band for ELF3.
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Disease free survival for 56 patients with early stage breast  cancer Figure 3
Disease free survival for 56 patients with early stage 
breast cancer. Comparing patients positive for RT-PCR 
markers (2 or more) with patients negative for RT-PCR 
markers (0 or 1).Journal of Hematology & Oncology 2009, 2:24 http://www.jhoonline.org/content/2/1/24
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Several studies have suggested that with the development
of improved detection techniques, detection of CTCs will
provide significant prognostic information [reviewed in
[11-15]].
Many recent studies have aimed to improve the methods
of detection and finding new markers for CTCs. Multi-
marker RT-PCR assays have become widely used for
detecting both lymph node involvement and CTCs in
breast cancer patients [e.g. [15-22]]. We previously
reported a panel of markers that allowed the sensitive and
specific identification of a single breast cancer line cell,
even if isolated with as many as 100 contaminating hae-
matopoietic cells [8]. We have now estimated the sensitiv-
ity of detection in reconstruction experiments using
immunobead capture of the MDA-MB453 breast cancer
cell line diluted into blood samples followed by RT-PCR
for the panel of markers. Seeding dilutions of MDA-
MB453 into normal blood resulted in consistent detec-
tion of all 5 RT-PCR markers at a level of 10 cells per ml of
blood (Figure 1). In samples containing 1 cell per ml of
blood (10 cells total), marker expression was detected in
2/3 samples indicating some loss of cells during the
immunobead isolation.
In the main part of this study, the expression of the panel
of 5 RT-PCR markers (TACSTD1, EPHB4, ELF3, EGFR, and
MGB1) was determined after immunobead enrichment of
circulating epithelial cells in blood samples obtained
from 56 early stage breast cancer patients. Circulating epi-
thelial cells were isolated from blood samples based on
their ability to bind to the immunobeads via the BerEP4
antibody that recognises the TACSTD1 (EpCAM/EGP2)
glycoprotein. Therefore, it was determined that patient
samples would only be considered positive for circulating
cells if TACSTD1  expression was positive along with
expression of one of the other markers.
Using this panel of markers, 20/56 (36%) of patient
blood samples had detectable levels of gene expression for
at least two of the markers including TACSTD1. As these
markers were previously shown to give sensitive and spe-
cific identification of tumour cells [8], it can be considered
that these patients must have had at least one epithelial
cell in that blood sample. Importantly, immunobead iso-
lates from 10 ml blood samples obtained from 10 normal
donor individuals with no seeded cells were negative for
expression of all markers.
Although the IB RT-PCR method is highly sensitive, it is
possible that some cells may not be isolated by the immu-
nobeads due to either the death of the cell during immu-
nobead incubation or lack of expression of the EpCAM
target antigen. In addition, it is likely there is some heter-
ogeneity in marker gene expression (where some cells
may not be expressing a particular gene at that time) in the
captured cells. This is demonstrated in the results of this
study where not all of the samples that are positive for at
least two markers are positive for all five markers and this
highlights the need for the use of multiple markers.
TACSTD1 and EPHB4 were expressed in 100% of samples
that were positive for two or more markers. As TACSTD1
encodes EpCAM, the target antigen for the BerEP4 anti-
body, it was expected that all captured tumour cells would
express this gene. Previous studies evaluating TACSTD1
expression as a marker of micrometastasis in breast cancer
reported expression of this gene in bone marrow and
peripheral blood cells of normal individuals [23-25].
However, those studies used nested-RT-PCR without prior
immunobead enrichment. In this study, TACSTD1 was an
excellent control marker for use with IB RT-PCR with
none of 10 normal control samples expressing the gene
after immunobead "enrichment".
EPHB4 has not been used as a marker of disseminated
breast tumour cells prior to this study. It has been used in
a previous immunobead RT-PCR study screening periph-
eral blood and lavage samples from patients with colorec-
tal cancer [26]. Wu et al (2004) used
immunohistochemistry of 94 tumour tissues to show that
82% of breast tumours had moderate to strong expression
of EPHB4 and that this was increased with clinical stage
and histological grade [27]. More recently, siRNA and
antisense studies have confirmed that EPHB4 has an
essential role in many processes that contribute to cancer
cell survival and spread in several cancers including breast
cancer [28]. EPHB4  was found to be an exceptional
marker in the present study, with 100% of positive patient
samples showing expression of the gene
EGFR and ELF3 (ESX) were expressed in the majority of
positive patient samples (81% and 90% respectively).
Both these genes have been reported to be over-expressed
in breast cancer [29-31]. EGFR has been widely used for
RT-PCR detection of CTCs [32-38]. The majority of these
studies found EGFR to be highly specific for CTCs with no
expression detected in normal control samples. EGFR
seems to be particularly associated with basal type breast
cancers and also may be a marker of the epithelial to mes-
enchymal transition often found in CTCs.
The final marker used in this study was MGB1 which has
been frequently used for detecting CTCs in breast cancer
patients due to its exclusive expression in breast tissue
[15,21,39-44]. In most of these reports, detection of
MGB1  was highly sensitive and specific with detection
ranging from 11% to 60% of patient samples. In this
study, MGB1 performed poorly as a marker of dissemina-
tion in comparison to the other 4 markers. Why MGB1Journal of Hematology & Oncology 2009, 2:24 http://www.jhoonline.org/content/2/1/24
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expression was not as readily detected as other markers is
unclear, but MGB1 was also the least frequently expressed
marker in the single cell assay reported previously [8]. It is
possible that as MGB1 is a marker of mammary differen-
tiation it may not be as highly expressed in breast tumours
with a relatively undifferentiated phenotype as the other
markers used here. This hypothesis is supported by a study
that found a significant association (p = 0.020) between
absence of MGB1 mRNA and grade 3 breast cancers [44].
Interestingly, MGB1 expression was not seen in the seven
RT-PCR marker positive patients with node negative dis-
ease and suggests there is either a low tumour cell burden
in the circulation of these patients or there are differences
in the biology of node negative tumours.
The relationships between positive RT-PCR marker
expression and prognostic indicators were analysed using
Fisher's exact test. As the TNM classification system deter-
mines stage of disease using tumour size, involvement of
lymph nodes, and distant metastasis, the relationship of
overall stage of disease and positive expression of markers
was examined. Positive results were seen in all stages of
disease and included a patient considered to have in situ
disease. Analysis showed there were significant associa-
tions with marker positivity with more advanced stage of
disease (in situ and Stage I versus Stage II p = 0.02) and
even within a stage (Stage IIa versus Stage IIb p = 0.03).
Tumour size was not strongly associated with marker pos-
itivity suggesting that even small tumours can shed cells
into the circulation. Similar results regarding tumour size
have also been observed in studies of breast cancer
patients with tumour cells in their bone marrow [45,46].
In contrast, a study using a quantitative RT-PCR multi-
marker assay of blood with tumour specific markers
reported a strong correlation with both clinical stage of
disease and tumour size [47].
Patients with Grade 3 tumours were more likely to be
marker positive in this study than patients with more dif-
ferentiated tumours. The majority (40%) of RT-PCR posi-
tive patients had Grade 3 tumours.
Lymph node involvement was strongly associated with
marker positivity, Lymph node involvement has also been
associated with the presence of micrometastatic cells in
the bone marrow [48]. However, a significant proportion
(17%) of node negative patients had CTCs detected by IB
RT-PCR. This is lower than the proportion (26%) of node
negative patients that had bone marrow micrometastases
[48]. These rates are similar to the reported 20–30% of
node negative patients that subsequently relapse or die.
The data from this study support the concept that LVI is a
good predictor that tumour cells are likely to have entered
the circulation. However, CTCs can be detected among
patients without evidence of lymphatic and or vascular
invasion (25% compared to 75% in lymphatic and or vas-
cular invasion positive group). A report of 1,258 patients
evaluated the absence or presence of LVI for any signifi-
cance towards assessing survival [49]. Presence of LVI was
found to be associated with a significantly worse survival
based on 12 year follow-up for those with lymph node
negative disease and an even worse survival for those with
positive nodes. It was suggested that both LVI and lymph
node status were highly independent and combined
together would be significant predictors of outcome.
Disease-free survival was not found to be significantly
associated with marker status however a definite trend
towards poorer disease free survival was observed. It is
likely that longer follow-up will reveal a statistically signif-
icant survival disadvantage for these patients.
The purpose of this study was to evaluate the methodol-
ogy of detection of CTCs in patients with operable breast
cancer. The results are compatible with the hypothesis
that CTCs are indicative of a higher risk of recurrence and
poorer survival even though statistical significance was
not reached. A limitation of the current study is that no
reference (housekeeping) genes were used when the study
was performed. This does not allow us to conclusively
eliminate the possibility that there may have been a small
proportion of false negative results. Nevertheless, the
multi-marker IB RT-PCR assay has been shown to sensi-
tively detect CTCs in early stage breast cancer patients. A
larger prospective study of minimal tumour burden in
blood, bone marrow and lymph nodes should provide
conclusive evidence of the role of detection of blood-
borne CTCs in early stage breast cancer.
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